Aequus Pharmaceuticals Inc. announced the launch of Zimed® PF, the first preservative-free multi-dose Bimatoprost for glaucoma patients in Canada.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.025 CAD | 0.00% | +25.00% | 0.00% |
1st Jan change | Capi. | |
---|---|---|
0.00% | 2.44M | |
+32.38% | 694B | |
+29.39% | 593B | |
-1.52% | 371B | |
+20.12% | 331B | |
+7.23% | 290B | |
+14.25% | 239B | |
-3.03% | 209B | |
+10.02% | 209B | |
+8.56% | 169B |
- Stock Market
- Equities
- AQS Stock
- News Aequus Pharmaceuticals Inc.
- Aequus Pharmaceuticals Inc. Announces Launch of Zimed PF in Canada